Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis | Zendy

John H. Stone | Zendy; Peter A. Merkel | Zendy; Robert Spiera | Zendy; Philip Seo | Zendy; Carol A. Langford | Zendy; Gary S. Hoffman | Zendy; Cees G. M. Kallenberg | Zendy; E. William St. Clair | Zendy; Anthony Turkiewicz | Zendy; Nadia K. Tchao | Zendy; Lisa Webber | Zendy; Linna Ding | Zendy; Lourdes P. Sejismundo | Zendy; Kathleen Mieras | Zendy; David Weitzenkamp | Zendy; David Iklé | Zendy; Vicki SeyfertMargolis | Zendy; Mark Mueller | Zendy; Paul Brunetta | Zendy; Nancy B. Allen | Zendy; Fernando C. Fervenza | Zendy; Duvuru Geetha | Zendy; Karina A. Keogh | Zendy; Eugene Y. Kissin | Zendy; Paul A. Monach | Zendy; Tobias Peikert | Zendy; Coen A. Stegeman | Zendy; Steven R. Ytterberg | Zendy; Ulrich Specks | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

Author(s) -

John H. Stone,

Peter A. Merkel,

Robert Spiera,

Philip Seo,

Carol A. Langford,

Gary S. Hoffman,

Cees G. M. Kallenberg,

E. William St. Clair,

Anthony Turkiewicz,

Nadia K. Tchao,

Lisa Webber,

Linna Ding,

Lourdes P. Sejismundo,

Kathleen Mieras,

David Weitzenkamp,

David Iklé,

Vicki SeyfertMargolis,

Mark Mueller,

Paul Brunetta,

Nancy B. Allen,

Fernando C. Fervenza,

Duvuru Geetha,

Karina A. Keogh,

Eugene Y. Kissin,

Paul A. Monach,

Tobias Peikert,

Coen A. Stegeman,

Steven R. Ytterberg,

Ulrich Specks

Publication year - 2010

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0909905

Subject(s) - rituximab , cyclophosphamide , medicine , vasculitis , anti neutrophil cytoplasmic antibody , immunology , regimen , anca associated vasculitis , antibody , chemotherapy , disease

Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research